```html

Nodal Basal Cell Carcinoma

Overview

Basal cell carcinoma (BCC) is the most common form of skin cancer, arising from basal cells in the epidermis. A nodular basal cell carcinoma (often simply called “nodular BCC”) is a specific subtype that presents as a raised, round or oval nodule. While most BCCs remain localized on sun‑exposed skin, nodular BCC can occasionally involve deeper structures, including regional lymph nodes—hence the term “nodal” when metastasis to nodes occurs, which is rare.

Who it affects: BCC is predominantly a disease of adults over 40, with incidence rising sharply after age 50. Men are slightly more affected than women, largely because of historically higher cumulative sun exposure. Individuals with fair skin (Fitzpatrick skin types I‑II), light hair, blue or green eyes, and a tendency to freckle are at greatest risk.

Prevalence: According to the American Cancer Society, >4.3 million cases of BCC are diagnosed each year in the United States, making it the most common cancer overall. Nodular BCC accounts for roughly 50‑60 % of all BCCs, whereas nodal metastasis from BCC is exceedingly uncommon—estimated at <0.03 % of cases (<sup>1</sup>).

Symptoms

The clinical picture of nodular BCC can vary, but the following signs are most frequently reported:

• Raised, pearly nodule – usually 5‑20 mm in diameter, with a smooth, dome‑shaped surface.
• Translucent or waxy appearance – the lesion may allow light to pass through, giving it a “shiny” look.
• Telangiectasias – fine, visible blood vessels (spider‑veins) radiating over the surface.
• Central ulceration – a small crater or crust often develops in the center (sometimes called a “rodent ulcer”).
• Bleeding or crusting – especially after minor trauma or rubbing.
• Itching or tenderness – some patients feel mild discomfort, although many nodules are painless.
• Growth over weeks to months – nodules tend to enlarge slowly but steadily.
• Regional lymph node enlargement – in the rare setting of nodal involvement, a firm, non‑tender lymph node may be palpable near the lesion (often in the neck or supraclavicular area).

Causes and Risk Factors

Primary cause

Nodular BCC, like other BCCs, is primarily caused by DNA damage in skin cells from ultraviolet (UV) radiation—both UVA (aging rays) and UVB (burning rays). The mutation most commonly involves the PTCH1 gene, a component of the Hedgehog signaling pathway, leading to uncontrolled cell growth.

Key risk factors

• Chronic sun exposure – lifetime cumulative UV dose, especially in early adulthood.
• History of sunburns – especially blistering burns before age 20.
• Fair skin, light hair, eye color – reduced melanin offers less natural UV protection.
• Family or personal history of skin cancer – genetic predisposition.
• Immunosuppression – organ‑transplant recipients, HIV infection, or long‑term corticosteroid use.
• Exposure to ionizing radiation – therapeutic radiation for other cancers can increase risk.
• Arsenic exposure – through contaminated water or occupational settings.
• Genetic syndromes – Gorlin‑Goltz syndrome (nevoid basal cell carcinoma syndrome) markedly raises BCC risk.

Diagnosis

Early and accurate diagnosis is essential because BCC rarely metastasizes but can cause extensive local destruction.

Clinical examination

A dermatologist will assess the lesion’s size, shape, color, and presence of telangiectasias or ulceration. Palpation of regional lymph nodes is performed if nodal involvement is suspected.

Dermatoscopy

Using a handheld dermatoscope, clinicians can visualize characteristic features such as:

• Shiny, white‑to‑pink background.
• Arborizing (branch‑like) vessels.
• Multiple small brownish dots (“blue‑gray globules”).

Biopsy

Definitive diagnosis requires histopathology.

• Punch or shave biopsy – most common; removes a core of tissue for microscopic analysis.
• Excisional biopsy – complete removal of the lesion, often performed when the nodule is small.
• Pathology will show nests of basaloid cells with peripheral palisading and stromal retraction.

Staging (if nodal disease is suspected)

• Ultrasound of the lymph node – assesses size and internal architecture.
• CT or MRI – provides detailed anatomy of deeper structures.
• PET‑CT – occasionally used to detect distant spread, though very rare in BCC.

Treatment Options

Therapy is individualized based on tumor size, location, depth, patient health, and whether nodes are involved.

Standard, skin‑limited nodular BCC

• Surgical excision – removal with 4‑6 mm margins; gold‑standard with >95 % cure rate.
• Mohs micrographic surgery – stepwise removal with immediate microscopic margin assessment; preferred for high‑risk areas (nose, periorbital, ears).
• Curettage and electrodessication – scraping the tumor followed by cauterization; suitable for low‑risk, small lesions.
• Radiation therapy – for patients who cannot undergo surgery; fractionated external‑beam radiation offers 90‑95 % control.
• Topical therapies – Imiquimod 5% cream or 5‑Fluorouracil (5‑FU) for superficial components, not typically first‑line for nodular BCC.
• Photodynamic therapy (PDT) – useful for superficial spread but limited efficacy for deep nodules.

Advanced disease with nodal involvement

• Wide local excision + lymphadenectomy – removal of the primary lesion plus affected lymph nodes.
• Hedgehog pathway inhibitors – oral Vismodegib or Sonidegib have shown response rates of 30‑45 % in metastatic BCC (FDA‑approved). Common side effects: muscle cramps, dysgeusia, hair loss.
• Systemic chemotherapy – rarely used; agents such as cisplatin or paclitaxel may be considered in clinical trials.
• Radiation – adjuvant postoperative radiotherapy improves local control when margins are positive.

Lifestyle and supportive measures

• Sun‑protective clothing and broad‑spectrum sunscreen (SPF 30 or higher) daily.
• Regular skin self‑exams and dermatologist visits (every 6–12 months).
• Smoking cessation – improves wound healing after surgery.

Living with Nodal Basal Cell Carcinoma

Even after successful treatment, ongoing care is important to prevent recurrence and manage the psychological impact.

Follow‑up schedule

• First postoperative visit at 1‑2 weeks to assess wound healing.
• Dermatology review at 3–6 months, then every 6‑12 months for at least 5 years.
• If nodes were removed, imaging (ultrasound or CT) may be repeated annually for 2 years.

Self‑surveillance

• Perform a full‑body skin check each month.
• Use a mirror or ask a partner to examine hard‑to‑see areas (back, scalp).
• Document any new or changing lesions with photos and dates.

Psychosocial support

• Consider counseling or support groups for skin‑cancer survivors.
• Skin‑related anxiety is common; cognitive‑behavioral therapy can reduce distress.

Rehabilitation after surgery

• Scar management – silicone gel sheets, pressure therapy, or laser resurfacing.
• Physical therapy if facial or neck surgery affects range of motion.

Prevention

Because UV exposure is the main modifiable cause, prevention focuses on sun safety.

• Daily sunscreen – apply 15‑30 minutes before going outdoors; reapply every 2 hours, and after swimming or sweating.
• Protective clothing – long‑sleeve shirts, wide‑brim hats, UV‑protective sunglasses.
• Avoid midday sun – schedule outdoor activities before 10 am or after 4 pm.
• Regular skin exams – by a professional and self‑examination.
• Vitamin D balance – obtain adequate vitamin D through diet or supplements rather than excessive sun exposure.
• Smoking cessation and healthy diet – may improve skin immunity.

Complications

If a nodular BCC is left untreated, it can cause:

• Local tissue destruction – ulceration, scarring, and loss of function (e.g., vision loss if near the eye).
• Bone invasion – especially on the nose or forehead.
• Secondary infection – due to chronic ulceration.
• Rare metastasis – spread to regional lymph nodes or, exceptionally, distant organs (lung, bone).
• Psychological impact – anxiety, body‑image concerns.

When to Seek Emergency Care

References

1. American Cancer Society. What Is Basal Cell Carcinoma? Updated 2023.
2. Mayo Clinic. Basal Cell Carcinoma – Symptoms and Causes. Accessed June 2024.
3. National Cancer Institute. Skin Cancer Treatment (PDQ®)–Patient Version. 2022.
4. WHO. Skin Cancers Fact Sheet. 2023.
5. Cleveland Clinic. Basal Cell Carcinoma. 2024.
6. Huang M, et al. Hedgehog pathway inhibitors in advanced basal cell carcinoma. J Clin Oncol. 2022;40(15):1620‑1629.

```